iCAD Named 2018 MedTech Breakthrough Award Winner
Company’s PowerLook®
Tomo Detection Solution Recognized as “Best New Radiology
Solution”
Nashua,
NH – June 6, 2018 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today announced
that its PowerLook®
Tomo Detection solution has been selected as the winner of the “Best New Radiology Solution” award by MedTech Breakthrough,
an independent organization recognizing the top companies, technologies and
products in the global health and medical technology market.
“We
are proud to be recognized by MedTech Breakthrough as a leading medical
technology company providing innovative solutions that support radiologists in
how they manage and interpret digital breast
tomosynthesis (DBT) data,” stated Ken Ferry,
president and CEO at iCAD. “It is exciting to see the impact that PowerLook
Tomo Detection has had on revolutionizing breast cancer detection acknowledged
by those in our industry.”
The
mission of the MedTech Breakthrough Awards is to honor excellence and recognize
the innovation, hard work and success in a range of health and medical
technology categories, including robotics, clinical administration, telehealth,
patient engagement, electronic health records (EHR), mHealth, medical devices, medical
data, and more. This year’s program attracted over 3,000 nominations from more
than 12 different countries across the world.
“iCAD is delivering leading-edge technology
with PowerLook Tomo Detection, an innovative radiologist workflow solution that
incorporates artificial intelligence (AI) to support and optimize workflow
efficiencies and decision making,” said James Johnson, managing
director, MedTech Breakthrough. “The use of AI and deep learning in healthcare
is one of the most exciting and promising developments in the medical technology
industry. We congratulate iCAD on their well-deserved industry recognition and
look forward to seeing continued success with their innovative solutions.”
PowerLook
Tomo Detection is the first
and only FDA-approved concurrent-read cancer detection solution for DBT. The
technology utilizes a trained algorithm developed through deep learning that
automatically analyzes each tomosynthesis plane. Suspicious areas identified
are then blended into a 2D synthetic image to provide radiologists with a
single, highly sensitive, enhanced image that is used to easily navigate the
tomosynthesis datasets.
About iCAD, Inc.
Headquartered
in Nashua, NH, iCAD is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit
www.icadmed.com.
“Safe Harbor” Statement
under the Private Securities Litigation Reform Act of 1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights,
product market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”,
“project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and
similar expressions identify forward-looking statements. Readers are cautioned not
to place undue reliance on those forward-looking statements, which speak only
as of the date the statement was made. The Company is under no obligation to
provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see
the disclosure contained in our public filings with the Securities and Exchange
Commission, including the 10-K for the year ended December 31, 2017, available
on the Investors section of our website at http://www.icadmed.com and on the
SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR
Erin Bocherer, (855) 300-8209
or
Investor Relations:
LifeSci Advisors
Jeremy Feffer, (917) 749-1494
About MedTech Breakthrough
The MedTech
Breakthrough Awards program, part of the Tech
Breakthrough Awards
organization, is devoted to honoring excellence in medical and health related
technology companies, products and people. The MedTech Breakthrough Awards
provide a platform for public recognition around the achievements of
breakthrough MedTech companies and products in categories including Patient
Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare
IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more
information visit www.MedTechBreakthrough.com.